GBB-101 is under clinical development by Great Bay Bio and currently in Phase II for Anemia in Chronic Kidney Disease (Renal Anemia). According to GlobalData, Phase II drugs for Anemia in Chronic Kidney Disease (Renal Anemia) have a 58% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how GBB-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

GBB-101 overview

GBB-101 is under development for the treatment of anemia caused by kidney damage. The drug candidate is administered through subcutaneous route. It is a long-acting anti-anemic agent. It acts by targeting the erythropoietin receptor.

Great Bay Bio overview

Great Bay Bio is a biotechnology company that creates biotechnological and biomedical products using artificial intelligence. The company is headquartered in Hong Kong.

For a complete picture of GBB-101’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.